BMSSC
CYTK icon

B. Metzler seel. Sohn & Co’s Cytokinetics CYTK Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,698
Closed -$248K – 767
2024
Q3 		$248K Hold
4,698
– – ﹤0.01% 737
2024
Q2 		$255K Hold
4,698
– – ﹤0.01% 732
2024
Q1 		$329K Buy
+4,698
New +$363K ﹤0.01% 675

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

B. Metzler seel. Sohn & Co's CYTK Position: Q4 2024 in Review

B. Metzler seel. Sohn & Co sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 4,698 shares — an estimated $248K sold.

B. Metzler seel. Sohn & Co first reported a position in CYTK in Q1 2024 and held it in 3 quarters. The position peaked at $329K in Q1 2024. 346 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

  • B. Metzler seel. Sohn & Co reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 4,698 Cytokinetics shares in Q4 2024, an estimated $248K.
  • B. Metzler seel. Sohn & Co first reported a position in Cytokinetics in Q1 2024 and held it in 3 quarters.
  • B. Metzler seel. Sohn & Co's Cytokinetics position peaked at $329K in Q1 2024.
  • 346 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q4 2024, filed 12 Feb 2025.